Why ProNAi Could Be the Biggest Loser at ASCO
The annual meeting for ASCO is generally one of the biggest weeks of the year for the health care sector. However, there are inevitably winners and losers.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 210
2 Analyst Biotech Stock Calls With Over 100% Upside Potential
The analysts at Wedbush focus in on two biotech companies that not only have data that could prove to be huge, but shares of each have been absolutely hammered over the past year,
Why Vascular Biogenics Is One of the Biggest Winners From ASCO So Far
As the annual meeting for the American Society of Clinical Oncology (ASCO) is underway, we are starting to see some winners shake out from it. Currently one of the biggest winners is Vascular Biogenics…
Why Ocular Therapeutix Is Sinking Despite Mixed Results
Ocular Therapeutix shares plunged early on Monday following less-than-favorable results, although the news was not all bad.
2 Small-Cap Speculative Biohealth Stocks Called to Double or Rise Exponentially
Many speculative calls are made on the biotech stocks. It is here that fortunes can easily be made. The dark side is that these speculative companies quite frequently fail to live up to their…
6 Biotechs Seriously on the Move
A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as recent trading activity and the consensus price target.
How the Cancer Drug Market Will Rise to $150 Billion by 2020
A new study from IMS Health has projected that the global market for cancer treatments rose to $107 billion in 2015.
NantHealth Explodes Into the Market With IPO
Nant Health entered the market with a bang on Thursday. Despite pricing at $14 per share, the stock opened at $16.11 and went higher.
Merrill Lynch Picks ASCO Winners
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking…
Clearside Biomedical Changes Up Pricing for IPO
Clearside Biomedical expects to price more than 7 million shares at $7 per share for an initial public offering valued up to nearly $58 million.
StemCells Reminds Investors of the Lessons of Outright Implosion
StemCells just reminded investors and speculators alike just how dangerous it can be to invest in biotech and biohealth companies.
AC Immune Files for IPO, Targeting Alzheimer’s and Parkinson’s
AC Immune has filed with the U.S. Securities & Exchange Commission (SEC) to pursue an initial public offering (IPO).
Jazz Pharma Pays $1.5 Billion for Celator
Jazz Pharmaceuticals announced Tuesday morning that it has reached a definitive agreement to acquire Celator Pharmaceuticals for about $1.5 billion.
Medtronic Beats Estimates, Provides Solid Guidance
Medical device maker Medtronic reported fourth-quarter and fiscal-year 2016 results before U.S. markets opened Tuesday morning.
Mississippi Is the Most Obese State
Mississippi has the most obese residents of any of the 50 states. As a by-product, cases of diabetes and the costs of health care are high, along with premature deaths.